Clinical Trial Update: Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Anbalcabtagene Autoleucel for relapsed/refractory primary central nervous system lymphoma and diffuse large B-cell lymphoma is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anbalcabtagene Autoleucel (anbalcabtagene autoleucel)

Snippet

Sponsor: Hyungwoo Cho | Conditions: Primary CNS Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING